The head of the government's drugs advisory body accuses pharmaceutical companies of driving up the price of medicine.
Researchers from the Johns Hopkins University
School of
medicine have entered into an agreement with Axela Inc. to use dotLabŪ technology in a clinical trial that evaluates circulating cardiac Troponin complexes (cTn) directly in patient samples. Dr. Jennifer Van Eyk, Director of the Johns Hopkins NHLBI Proteomics Center (JHNBPC) in Baltimore, U.S.A., is the lead researcher for this trial.